(see earlier workshops below)
IPECAD modelling workshop 3 – 2021 (network meeting)
IPECAD modelling workshop – network meeting 2021, September (virtual).
We are pleased to announce the next IPECAD modelling workshop.
We aim to host a network meeting on decision modelling in Alzheimer’s disease and related dementias to provide an update of former workshop members on modelling developments, to hear from invited external speakers on the value of model outcomes cross-comparison, and share a plan for the modelling cross-comparison workshop aimed for 2022.
We would like to invite you to this workshop. Please be aware is has limited spaces available. Use this form to leave your contact details and background information for receiving more information to stay up to date with the workshop details:
Tuesday September 21 from 15.00-18.00h (CEST), which is 06.00-09.00h Los Angeles and 09.00-12.00h Boston time.
15.00 (40m) Update on current activities related to decision modeling in AD and related dementias (all IPECAD modelling workshop 2020 participants).
15.40 (15m) break
15.55 (40m) Current use and potential of model cross-comparisons in HTA decision-making
Guest speaker: Anja Schiel, Norwegian Medicines Agency)
Guest speaker: Kit Simpson, Medical University of South Carolina, U.S.
2 x 10-minute presentation, followed by 20-minute discussion.
16.35 (15m) break
16.50 (45m) Looking back at the 2020 IPECAD modelling workshop cross-comparison: update on manuscript and plan for next (2022) IPECAD modelling workshop (IPECAD steering).
17.35 (25m) Closing and room for informal chatting.
18.00 End of meeting.
With best regards,
On behalf of the organizing committee, IPECAD Modelling Group
IPECAD modelling workshop 2 – 2020
Comparison of Cost-Effectiveness/Disease Progression (Health Economic) Models in Alzheimer’s Disease – NETWORK Meeting, 2020
Trust and confidence are critical to the successful use of decision-analytic health care models. The aim of this meeting is to improve the transparency and trust aligned to use of health economic models in the context of Alzheimer’s disease (AD). This will be achieved through ongoing development of methods, improved reporting standards, and related good practice within the field of decision-analytic modelling in the area of AD. The key objective of this upcoming meeting is to receive submissions on AD modelling aligned to the challenge/scenarios set out, and to systematically examine cross-model differences in predicted outcomes, with structured discussion in relation to model design choices and parameterization. The meeting is based on a reference case benchmark scenario (and requested output matrix) – developed through prior discussion – that can be run in multiple health economic models of Alzheimer’s Disease (AD), and which will allow comparison of model predictions and facilitate identification of possible factors explaining the range of and heterogeneity across modelling and simulation outcomes.
IPECAD modelling workshop 1 – 2019
AD Modelling Workshop, 19th-20th September, 2019, Stockholm, Sweden.
The IPECAD modelling group is planning an upcoming inaugural IPECAD workshop on modelling methods aligned to the health policy context for Alzheimer’s disease. This workshop is invitation only, and aimed at people who are research active in this area, and those in close collaborations with people/teams who are research active in this area.
In this workshop we wish to bring together people who are active in the area of Alzheimer’s disease decision-modelling, and who are developing modelling methods in the context of cost-effectiveness analyses and health technology assessment, or disease progression models that may be used in this way.
We plan for this workshop to be the first of a future series of meetings and activities to further the development of modelling methods, and the identification of data to populate decision-models, in the area of Alzheimer’s disease (AD). Whilst the initial focus is on AD, we hope to be able to extend the scope of our future activity into and across related dementias, and across the full diagnostic and treatment pathways associated with dementia.
We aim to increase understanding of modelling methods in the area of Alzheimer’s disease and to facilitate methodological development, transparency and comparability, with a view to further developing methods available to support the ambition of rapid access to effective and cost-effective care for people affected by AD, and related dementias.
On behalf of the IPECAD Modelling Group
Dr. Linus Jönsson – Karolinska Institutet, Sweden; H. Lundbeck A/S, Denmark,
Prof. Colin Green – University of Exeter, UK,
Dr. Ron Handels – Karolinska Institutet, Sweden; Maastricht University, Netherlands
Prof. Bengt Winblad – Karolinska Institutet, Sweden
Prof. Anders Wimo – Karolinska Institutet, Sweden
Dr. Anders Gustavsson – Karolinska Institutet, Sweden; Quantify Research, Sweden
Dr. Anders Sköldunger – Karolinska Institutet, Sweden